ARTV
Artiva Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.19
+0.58%Jun 8, 2026, 10:30 UTC
The U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Artiva Biotherapeutics' AlloNK plus rituximab for refractory rheumatoid arthritis.
Source: